Skip to main content

Advertisement

Table 4 Characteristics of studies comparing outcome for continuous versus intermittent administration of carbapenems

From: Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?

Study Drug Patient population Dosage Study type Outcome measure Outcome Remarks
*Lorente 2006 [53] Meropenem VAP with gram negative bacilli 4 g/d CI (n = 42) vs. 4 x 1 g/d (n = 47) Retrospective cohort study Clinical cure CI > II(p  < 0.001)  
*Sakka 2007 [44] Imipenem-cilastatin Nosocomial pneumonia 2 g/d CI (n = 10) vs. 3 x 1 g/d (n = 10) RCT Clinical cure NS Lower antimicrobial dose in CI groupT > MIC = 100 % in both II and CI group
  1. *Studies that included critically ill, ICU patients.
  2. VAP = ventilator-associated pneumonia; RCT = randomized, controlled trial.